Endomyocardial biopsy (EMB) is an invasive procedure originally developed for the
monitoring of heart transplant rejection. Over the year, this procedure has gained a …

Heart transplantation has become a standard therapy option for advanced heart failure. The
translation of heart transplantation from innovative experiments to long-term clinical success …

Cochrane, Maria Crespo Leiro, Anne Dipchand, Brian Feingold, Kathleen Grady, Edward
Horn, Maryl Johnson, Donna Mancini, Sean Pinney, Heather Ross, Kari Wujcik, Andreas …

Endomyocardial biopsy (EMB) screening represents the standard of care for detecting
allograft rejections after heart transplant. Manual interpretation of EMBs is affected by …

Monitoring allograft health is an important component of posttransplant therapy.
Endomyocardial biopsy is the current gold standard for cardiac allograft monitoring but is an …

Standardized donor-derived cell-free DNA (dd-cfDNA) testing has been introduced into
clinical use to monitor kidney transplant recipients for rejection. This report describes the …

The use of circulating cell-free DNA (cfDNA) as a biomarker in transplant recipients offers
advantages over invasive tissue biopsy as a quantitative measure for detection of transplant …

Heart transplantation is advocated in selected patients with advanced heart failure in the
absence of contraindications. Principal challenges in heart transplantation centre around an …

The authors conducted a prospective trial to assess the feasibility of real time central
molecular assessment of kidney transplant biopsy samples from 10 North American or …

The molecular mechanisms operating in human organ transplant rejection are best inferred
from the mRNAs expressed in biopsies because the corresponding proteins often have low …